Swedish Orphan Biovitrum AB (publ): Sobi appoints Kirsti Gjellan as Senior Vice President Manufacturing Operations

| Source: Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that Kirsti Gjellan
has been appointed Senior Vice President Manufacturing Operations. Gjellan joins
Sobi from global pharmaceutical company Pfizer where she has been Managing
Director and Site Leader at the Strängnäs site for Pfizer Health AB as well as
Member of the Pfizer Health AB Board.

A Ph.D. in Pharmaceutical Technology, Kirsti Gjellan brings a strong track
record from leading positions within both Pfizer and AstraZeneca. She has
experience from working both with quality and manufacturing and her achievements
have been both internally and externally awarded. In 2006 Gjellan was honoured
with Pfizer's John Mitchell Quality Award and in 2013 she was named Swedish
Pharma Profile of the Year.

"We are delighted to welcome Kirsti to Sobi", said Geoffrey McDonough, President
and CEO at Sobi. "Kirsti will continue to build on the legacy of our biologics
manufacturing organisation, and to prepare us for our future products for
patients with rare diseases. Kirsti will also be a great addition to our senior
leadership team."

"I'm very much looking forward to my new role and to, together with Sobi's
Leadership team and all new colleagues, work to bring new therapies for rare
diseases to patients who don't have access to medicines today," said Kirsti

Kirsti Gjellan will join Sobi in September 2014. She takes over after Lena
Nyström who will retire later this year.


About Sobi

Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Inflammation and Genetic diseases, with two late stage biological
development projects within Haemophilia. We also market a portfolio of specialty
and rare disease products for partner companies. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion
($334 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com.

For more information - not for publication

  Media relations          Investor relations

Oskar Bosson, Head of      Jörgen Winroth, Vice President, Head of Investor
Communications             Relations

T: +46 70 410 71 80        T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135

oskar.bosson@sobi.com      jorgen.winroth@sobi.com

The above information was released for public distribution on 26 May 2014, at
15:30 CET.